Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLB Stock Forecast 2026-2027
$11.15
Current Price
$513.98M
Market Cap
Buy 1
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to CLB Price Targets
+97.3%
To High Target of $22.00
+21.1%
To Median Target of $13.50
+7.6%
To Low Target of $12.00
CLB Price Momentum
-2.7%
1 Week Change
-16.0%
1 Month Change
-11.3%
1 Year Change
-30.4%
Year-to-Date Change
-45.2%
From 52W High of $20.36
+14.7%
From 52W Low of $9.72
📊 TOP ANALYST CALLS
Did CLB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Core Labs is one of their latest high-conviction picks.
Latest CLB Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, CLB has a neutral consensus with a median price target of $13.50 (ranging from $12.00 to $22.00). The overall analyst rating is Buy (6.0/10). Currently trading at $11.15, the median forecast implies a 21.1% upside. This outlook is supported by 1 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Stephen Gengaro at Stifel, projecting a 97.3% upside. Conversely, the most conservative target is provided by Stephen Gengaro at Stifel, suggesting a 7.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLB Analyst Ratings
1
Buy
1
Hold
1
Sell
CLB Price Target Range
Low
$12.00
Average
$13.50
High
$22.00
Current: $11.15
Latest CLB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 16, 2025 | Stifel | Stephen Gengaro | Hold | Maintains | $12.00 |
| May 13, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Apr 15, 2025 | Stifel | Hold | Maintains | $N/A | |
| Mar 12, 2025 | Citigroup | Neutral | Upgrade | $N/A | |
| Feb 20, 2025 | Citigroup | Sell | Maintains | $N/A | |
| Oct 31, 2024 | Citigroup | Sell | Maintains | $N/A | |
| Jul 26, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $22.00 |
| Jul 15, 2024 | B of A Securities | Chase Mulvehill | Underperform | Maintains | $15.00 |
| Jul 15, 2024 | Piper Sandler | Luke Lemoine | Neutral | Maintains | $17.00 |
| Apr 26, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $18.00 |
| Apr 15, 2024 | B of A Securities | Chase Mulvehill | Underperform | Maintains | $16.00 |
| Feb 5, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $17.00 |
| Jan 29, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $21.00 |
| Sep 18, 2023 | Citigroup | Scott Gruber | Sell | Maintains | $20.00 |
| Jul 31, 2023 | Piper Sandler | Luke Lemoine | Neutral | Maintains | $21.00 |
| Jun 30, 2023 | Citigroup | Scott Gruber | Sell | Downgrade | $21.00 |
| May 1, 2023 | Piper Sandler | Luke Lemoine | Neutral | Maintains | $19.00 |
| Apr 28, 2023 | Stifel | Stephen Gengaro | Hold | Maintains | $25.00 |
| Apr 18, 2023 | B of A Securities | Chase Mulvehill | Underperform | Downgrade | $21.50 |
| Feb 7, 2023 | Citigroup | Scott Gruber | Neutral | Maintains | $26.00 |
Core Laboratories Inc. (CLB) Competitors
The following stocks are similar to Core Labs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Core Laboratories Inc. (CLB) Financial Data
Core Laboratories Inc. has a market capitalization of $513.98M with a P/E ratio of 18.2x. The company generates $524.73M in trailing twelve-month revenue with a 5.5% profit margin.
Revenue growth is -1.4% quarter-over-quarter, while maintaining an operating margin of +1.6% and return on equity of +11.1%.
Valuation Metrics
Market Cap
$513.98M
Enterprise Value
$679.55M
P/E Ratio
18.2x
PEG Ratio
0.0x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
-1.4%
Gross Margin
+13.1%
Operating Margin
+1.6%
Net Margin
+5.5%
EPS Growth
-1.4%
Financial Health
Cash/Price Ratio
+4.4%
Current Ratio
2.0x
Debt/Equity
61.0x
ROE
+11.1%
ROA
+4.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Core Laboratories Inc. (CLB) Business Model
About Core Laboratories Inc.
What They Do
Provides reservoir services to the oil and gas industry.
Business Model
The company generates revenue by offering advanced reservoir description, production enhancement, and management services to oil and gas companies. By utilizing cutting-edge technology and specialized expertise in fluid analysis, PVT testing, and core analysis, Core Laboratories helps clients optimize their production capabilities and enhance hydrocarbon extraction efficiency.
Additional Information
Core Laboratories is headquartered in Amsterdam and operates in major energy-producing regions globally. The company focuses on innovation and sustainability, playing a crucial role in the energy sector by improving recovery techniques and resource management for its clients.
Company Information
Sector
Energy
Industry
Oil & Gas Equipment & Services
Employees
3,300
CEO
Mr. Lawrence V. Bruno
Country
United States
IPO Year
1995
Website
www.corelab.comCore Laboratories Inc. (CLB) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Liberty Energy Stock Surges 96% in a Year: Is There More Upside Ahead?
LBRT stock surges 96% in a year, but can demand for premium services, power expansion and technology innovation drive further gains amid key risks?
Jul 07, 2026
By Zacks Equity Research
Analyst Blog
Latest News
CORE LABORATORIES ANNOUNCES TIMING OF SECOND QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
9 days ago
Quick Summary
Core Laboratories (NYSE: CLB) will hold its Q2 2026 conference call for investors and analysts on June 30, 2026, at 7:30 a.m. CDT.
Why It Matters
Core Laboratories' Q2 2026 conference call signals upcoming insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CLB is experiencing ongoing geopolitical uncertainty, reduced laboratory activity, cost inflation, and delayed shipments, which hinder prospects for a robust recovery.
Why It Matters
CLB's challenges may lead to reduced profitability and growth potential, increasing risks for investors and potentially impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Core Laboratories (CLB) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters
Core Laboratories' recent earnings report can influence stock performance and investor sentiment, impacting future price movements and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Investors should monitor CLB stock due to recent activity in the options market, indicating potential changes in investor sentiment or expectations.
Why It Matters
Increased activity in the options market for CLB stock may indicate rising volatility or investor sentiment, which can impact stock price and trading strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
CLB's Q1 earnings met estimates but declined year-over-year due to a revenue miss and disruptions in the Middle East affecting key segments.
Why It Matters
CLB's Q1 earnings matching estimates yet declining year-over-year signals potential weaknesses in revenue and operations, which could impact future growth and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Core Laboratories Inc. (CLB) held its Q1 2026 earnings call, discussing financial performance and operational updates. Further details on earnings and projections were provided.
Why It Matters
Core Laboratories' Q1 2026 earnings reveal financial health and operational performance, impacting stock valuation and investor sentiment regarding future growth.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CLB Stock
What is Core Laboratories Inc.'s (CLB) stock forecast for 2027?
Based on our analysis of 12 Wall Street analysts, Core Laboratories Inc. (CLB) has a median price target of $13.50. The highest price target is $22.00 and the lowest is $12.00.
Is CLB stock a good investment in 2027?
According to current analyst ratings, CLB has 1 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $11.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLB stock?
Wall Street analysts predict CLB stock could reach $13.50 in the next 12 months. This represents a 21.1% increase from the current price of $11.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Core Laboratories Inc.'s business model?
The company generates revenue by offering advanced reservoir description, production enhancement, and management services to oil and gas companies. By utilizing cutting-edge technology and specialized expertise in fluid analysis, PVT testing, and core analysis, Core Laboratories helps clients optimize their production capabilities and enhance hydrocarbon extraction efficiency.
What is the highest forecasted price for CLB Core Laboratories Inc.?
The highest price target for CLB is $22.00 from Stephen Gengaro at Stifel, which represents a 97.3% increase from the current price of $11.15.
What is the lowest forecasted price for CLB Core Laboratories Inc.?
The lowest price target for CLB is $12.00 from Stephen Gengaro at Stifel, which represents a 7.6% increase from the current price of $11.15.
What is the overall CLB consensus from analysts for Core Laboratories Inc.?
The overall analyst consensus for CLB is neutral. Out of 12 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $13.50.
How accurate are CLB stock price projections?
Stock price projections, including those for Core Laboratories Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 5:21 PM UTC